David Kandzari, MD, from the Piedmont Heart Institute, led a group of researchers to assess the cost-effectiveness of renal denervation based on clinical event risk reduction, quality of life measures and projected lifetime costs. Data from the SPYRAL HTN-ON MED study was used for the assessment.
“The cost-effectiveness of [renal denervation] was robust across a broad range of scenarios and sensitivity analyses,” the researchers wrote.
The study found that renal denervation had an incremental cost-effectiveness ratio of $32,732 per quality-adjusted life years. Ratios below $50,000 per quality-adjusted life years are considered to indicate an intervention is cost-effective and has “high value,” according to an Aug. 23 TCTMD report.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
